Equillium to present at the jmp securities life sciences conference

La jolla, calif., june 09, 2021 (globe newswire) -- equillium, inc. (nasdaq: eq), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, announced today that it will present at the jmp securities life sciences conference, a virtual investor event, taking place june 16 and 17, 2021.
EQ Ratings Summary
EQ Quant Ranking